Kazuho Inoko

Dr. Kazuho Inoko

Surgery, University of Minnesota, Minneapolis, Minnesota, USA
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
Verified
Journal Article
Open access
KIKazuho Inoko
Kazuho Inoko
YEYuma Ebihara
Yuma Ebihara
KSKeita Sakamoto
Keita Sakamoto
NMNoriyuki Miyamoto
Noriyuki Miyamoto
YKYo Kurashima
Yo Kurashima
SHSatoshi Hirano
Satoshi Hirano
In performing SVP-LSPDP, it is effective to make a strategic choice between 2 different approaches according to the course of splenic artery.

25 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
HKHiroki Kushiya
Hiroki Kushiya
KHKei Hiraoka
Kei Hiraoka
TSTomohiro Suzuki
Tomohiro Suzuki
KIKazuho Inoko
Kazuho Inoko
AIAkihito Inagaki
Akihito Inagaki
SHSatoshi Hirano
Satoshi Hirano
Therapeutic efficacy of retroviral replicating vector (RRV)-mediated prodrug activator gene therapy has been demonstrated in a variety of tumor models, but clinical investigation of this approach has so far been restricted to glioma and gastrointestinal malignancies. In the present study, we evaluated replication kinetics, transduction efficiency, and therapeutic efficacy of RRV in experimental models of lung cancer. RRV delivering GFP as a reporter gene showed rapid viral replication in a panel of lung cancer cells in vitro, as well as robust intratumoral replication and high levels of tumor transduction in subcutaneous and orthotopic pleural dissemination models of lung cancer in vivo. Toca 511 (vocimagene amiretrorepvec), a clinical-stage RRV encoding optimized yeast cytosine deaminase (yCD) which converts the prodrug 5-fluorocytosine (5-FC) to the active drug 5-fluorouracil (5-FU), showed potent cytotoxicity in lung cancer cells upon exposure to 5-FC prodrug. In vivo, Toca 511 achieved significant tumor growth inhibition following 5-FC treatment in subcutaneous and orthotopic pleural dissemination models of lung cancer in both immunodeficient and immunocompetent hosts, resulting in significantly increased overall survival. This study demonstrates that RRV can serve as highly efficient vehicles for gene delivery to lung cancer, and indicates the translational potential of RRV-mediated prodrug activator gene therapy with Toca 511/5-FC as a novel therapeutic strategy for pulmonary malignancies.

1 July 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
HKHiroki Kushiya
Hiroki Kushiya
KHKei Hiraoka
Kei Hiraoka
TSTomohiro Suzuki
Tomohiro Suzuki
KIKazuho Inoko
Kazuho Inoko
AIAkihito Inagaki
Akihito Inagaki
SHSatoshi Hirano
Satoshi Hirano
Therapeutic efficacy of retroviral replicating vector (RRV)-mediated prodrug activator gene therapy has been demonstrated in a variety of tumor models, but clinical investigation of this approach has so far been restricted to glioma and gastrointestinal malignancies. In the present study, we evaluated replication kinetics, transduction efficiency, and therapeutic efficacy of RRV in experimental models of lung cancer. RRV delivering GFP as a reporter gene showed rapid viral replication in a panel of lung cancer cells in vitro, as well as robust intratumoral replication and high levels of tumor transduction in subcutaneous and orthotopic pleural dissemination models of lung cancer in vivo. Toca 511 (vocimagene amiretrorepvec), a clinical-stage RRV encoding optimized yeast cytosine deaminase (yCD) which converts the prodrug 5-fluorocytosine (5-FC) to the active drug 5-fluorouracil (5-FU), showed potent cytotoxicity in lung cancer cells upon exposure to 5-FC prodrug. In vivo, Toca 511 achieved significant tumor growth inhibition following 5-FC treatment in subcutaneous and orthotopic pleural dissemination models of lung cancer in both immunodeficient and immunocompetent hosts, resulting in significantly increased overall survival. This study demonstrates that RRV can serve as highly efficient vehicles for gene delivery to lung cancer, and indicates the translational potential of RRV-mediated prodrug activator gene therapy with Toca 511/5-FC as a novel therapeutic strategy for pulmonary malignancies.

1 January 2015 in World Journal of Gastroenterology
Verified
Journal Article
Open access
KIKazuho Inoko
Kazuho Inoko
TTTakahiro Tsuchikawa
Takahiro Tsuchikawa
TNTakehiro Noji
Takehiro Noji
YKYo Kurashima
Yo Kurashima
YEYuma Ebihara
Yuma Ebihara
SHSatoshi Hirano
Satoshi Hirano
This report describes a rare case of hilar cholangiocarcinoma with intratumoral calcification that mimicked hepatolithiasis. A 73-year-old man presented to a local hospital with a calcified lesion in the hepatic hilum. At first, hepatolithiasis was diagnosed, and he underwent endoscopic stone extraction via the trans-papillary route. This treatment strategy failed due to biliary stricture. He was referred to our hospital, and further examination suggested the existence of cholangiocarcinoma. He underwent left hepatectomy with caudate lobectomy and extrahepatic bile duct resection. Pathological examination revealed hilar cholangiocarcinoma with intratumoral calcification, while no stones were found. To the best of our knowledge, only one case of calcified hilar cholangiocarcinoma has been previously reported in the literature. Here, we report a rare case of calcified hilar cholangiocarcinoma and reveal its clinicopathologic features.

1 July 2023 in Viruses
Verified
Journal Article
Open access
PDF file
CLChristopher LaRocca
Christopher LaRocca
KJKari L Jacobsen
Kari L Jacobsen
KIKazuho Inoko
Kazuho Inoko
SZStanislav Zakharkin
Stanislav Zakharkin
MYMasato Yamamoto
Masato Yamamoto
JDJulia Davydova
Julia Davydova
There have been numerous advances in gene therapy and oncolytic virotherapy in recent years, especially with respect to cutting-edge animal models to test these novel therapeutics. With all of these advances, it is important to understand the biosafety risks of testing these vectors in animals. We performed adenovirus-based viral shedding studies in murine models to ascertain when it is appropriate to downgrade the animals from Biosafety Level (BSL) 2 to BSL 1 for experimental handling and transport. We utilized intravenous injections of a replication-competent adenovirus and analyzed viral shedding via the collection of buccal and dermal swabs from each animal, in addition to obtaining urine and stool samples. The adenovirus hexon copy number was determined by qPCR, and plaque formation was analyzed to assess the biologic activity of viral particles. Our results demonstrate that after 72 h following viral inoculation, there is no significant quantity of biologically active virus shedding from the animals. This observation suggests that on day 4 following adenovirus injection, mice can be safely downgraded to BSL 1 for the remainder of the experiment with no concern for hazardous exposure to laboratory personnel.

23 July 2024 in Cancer Gene Therapy
Verified
Journal Article
Closed access
PDF file
HNHiroki Niwa
Hiroki Niwa
TNToru Nakamura
Toru Nakamura
HKHiroki Kushiya
Hiroki Kushiya
TKTomotaka Kuraya
Tomotaka Kuraya
KIKazuho Inoko
Kazuho Inoko
SHSatoshi Hirano
Satoshi Hirano